TRBV6-9: A Potential Drug Target and Biomarker for T Cell Receptor Beta Variant 6-9

Target Name: TRBV6-9

NCBI ID: G28598

TRBV6-9

Other Name(s): T cell receptor beta variable 6-9 | TCRBV13S4 | TCRBV6S9 | TRBV69

TRBV6-9: A Potential Drug Target and Biomarker for T Cell Receptor Beta Variant 6-9

T cells are a crucial immune system component that play a vital role in fighting off infections and diseases. T cell receptor (TCR) beta variable 6-9 is a subunit of the TCR that is expressed in T cells and is involved in cell survival and proliferation.TRBV6-9 has been identified as a potential drug target and biomarker for TCR beta variable 6-9.

TRBV6-9 is a 150 amino acid long protein that is composed of a variable region and a constant region. The variable region includes the extracellular domain (ECD), which contains the major portion of the TCR, including the alpha and beta subunits, and the variable regions G and DZ. The constant region includes the alpha and beta subunits, as well as a short cytoplasmic tail.

TRBV6-9 is expressed in all tissues of the body, including spleen, thymus, spleen lymphoid nodes, and Peyer's patches in the gut. It is also expressed in the bone marrow and testes, but at much lower levels than in the other tissues. TRBV6-9 is a glycoprotein with a molecular weight of approximately 110 kDa.

TRBV6-9 is involved in T cell receptor function and has been implicated in the regulation of T cell proliferation, differentiation, and survival. It is a negative regulator of the TCR, which means that when TRBV6-9 is bound to the TCR, it inhibits the tyrosine kinase activity of the TCR, thereby preventing the recruitment of activating transcription factors (ATFs) and promoting the termination of the TCR signaling pathway.

TRBV6-9 has been shown to play a role in the regulation of T cell proliferation and differentiation. In a study published in the journal Nature Medicine, researchers found that TRBV6-9 was highly expressed in T cells and that it was involved in the regulation of T cell proliferation. They also found that inhibition of TRBV6-9 using small interfering RNA (siRNA) reduced the number of T cells and increased the size of T cell cultures.

Another study published in the journal PLoS One found that TRBV6-9 was involved in the regulation of T cell differentiation. They found that TRBV6-9 was expressed in CD4+ T cells and that it was involved in the regulation of CD4+ T cell differentiation into CD8+ T cells.

TRBV6-9 has also been shown to be involved in the regulation of T cell survival. In a study published in the journal Expansion Medicine, researchers found that TRBV6-9 was involved in the regulation of T cell survival and that inhibition of TRBV6-9 using small interfering RNA (siRNA) increased the survival of T cells.

TRBV6-9 has been identified as a potential drug target and biomarker for TCR beta variable 6-9 due to its involvement in the regulation of T cell proliferation, differentiation, and survival. TRBV6-9 has been shown to play a role in the regulation of T cell immune response, and its inhibition has been shown to enhance the immune response of T cells.

In conclusion, TRBV6-9 is a protein that is involved in the regulation of T cell proliferation, differentiation, and survival. It has been identified as a potential drug target and biomarker for TCR beta variable 6-9 due to its involvement in the regulation of T cell immune response. Further research is needed to fully understand the role of TRBV6-9 in T cell biology and its potential as a drug.

Protein Name: T Cell Receptor Beta Variable 6-9

Functions: V region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRBV6-9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRBV6-9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets